FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 11/2024”.
The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of November 2024 we identified the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding reached EUR 32,558m
- Biotech/Pharma received 53% of the total investment volume (EUR 17,215m) with oncology being the leading indication (28%)
- In November Trace Neuroscience secured the highest transaction volume with EUR 93m, followed by TrexBio with EUR 78m and ZAP Surgical with EUR 72m
- RA Capital Management (United States) is the most active investor (by deal volume in 2024), followed by ARCH Venture Partners (United States) and Atlas Venture (United States)
To access the full report, please click here.